Evidence from current practice provided by NHS England and analysed by NICE indicates that digital therapies recommended for PTSD could save over 5,000 hours of therapist time per 1,000 people. Almost ...

Suggested remit: To appraise the clinical and cost effectiveness of Itulazax 12 standardised quality pollen from white birch (betula verrucosa) sublingual lyophilisate immunotherapy (12 SQ-Bet SLIT) ...

A list of downloadable documents created during development.

Rucaparib (Rubraca) is available on the NHS. It is a possible maintenance treatment for relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has ...

There is a simple discount patient access scheme for rucaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by the lead team of committee A, which includes the chair and vice chair. Committee members ...

Rucaparib is recommended, within its marketing authorisation, as an option for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'inputs and eligible population' and 'unit costs' worksheets in the template to reflect ...

Rucaparib (Rubraca, Pharm&) is indicated 'as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary ...